米国の男性型脱毛症市場規模、シェア、動向分析レポート：治療別、販売チャネル別、性別、最終用途別、セグメント予測、2025-2030年

米国の男性型脱毛症市場動向：

米国の男性型脱毛症市場は、2024年には9億7,910万米ドルとなり、2025年から2030年にかけてCAGR 6.6%で成長すると予測されています。

男性型脱毛症（AGA）の罹患率の増加が市場成長の原動力となっています。最も一般的な脱毛症である男性型脱毛症は、人口のかなりの部分が罹患しており、加齢や遺伝的要因が一役買っています。薄毛対策に対する認識が高まるにつれ、治療を求める人が増え、市場が拡大しています。国立医学図書館が2023年7月に発表したデータによると、米国では男性約5,000万人、女性約3,000万人が男性型脱毛症（AGA）に罹患しています。

もう一つの要因は、治療オプションの進歩です。同市場では、外用液、経口薬、多血小板血漿（PRP）療法や植毛手術などの低侵襲手術など、革新的な治療法の導入が見られます。製薬会社もまた、より効果的で利便性の高い治療法を開発するために研究開発に投資しており、幅広い消費者層を惹きつけています。

新薬の承認と市販品の拡大は、市場の成長をさらに促進します。2025年6月、ペラージ・ファーマシューティカルズは、休止状態の毛包幹細胞を再活性化することで脱毛をターゲットにした局所治療薬PP405の第2a相臨床試験で良好な結果が得られたと発表しました。この進歩により、ペラージ社は男性型脱毛症の再生医療におけるリーダー的存在となります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の男性型脱毛症市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 米国の男性型脱毛症市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
• 米国の男性型脱毛症市場：パイプライン分析

第4章 米国の男性型脱毛症市場：治療の推定・動向分析

• 治療セグメントダッシュボード
• 米国の男性型脱毛症市場：治療変動分析
• 米国の男性型脱毛症市場規模と動向分析（治療別、2018～2030年）
• 医薬品
• デバイス

第5章 米国の男性型脱毛症市場：最終用途の推定・動向分析

• 最終用途セグメントダッシュボード
• 米国の男性型脱毛症市場：最終用途変動分析
• 米国の男性型脱毛症市場の規模と動向分析（最終用途別、2018～2030年）
• 在宅ケア設定
• 皮膚科クリニック

第6章 米国の男性型脱毛症市場：販売チャネルの推定・動向分析

• 販売チャネルセグメントダッシュボード
• 米国の男性型脱毛症市場：販売チャネル変動分析
• 米国の男性型脱毛症市場規模と動向分析（販売チャネル別、2018年～2030年）
• 処方箋
• 市販薬

第7章 米国の男性型脱毛症市場：性別の推定・動向分析

• 男性
• 女性

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Key company heat map analysis, 2024
• 企業プロファイル
  • Johnson &Johnson Services, Inc.
  • Cipla
  • Sun Pharmaceutical Industries Ltd.
  • Merck &Co., Inc
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Hairmax International LLC
  • Freedom Laser Therapy, Inc.（iRESTORE Hair Growth System）
  • Curallux, LLC
  • Apira Science, Inc.（iGROW Laser）
  • Theradome Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 3 U.S. androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 4 U.S. androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 5 U.S. androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. androgenetic alopecia market: market outlook
• Fig. 10 U.S. androgenetic alopecia competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. androgenetic alopecia market driver impact
• Fig. 16 U.S. androgenetic alopecia market restraint impact
• Fig. 17 U.S. androgenetic alopecia market strategic initiatives analysis
• Fig. 18 U.S. androgenetic alopecia market: Treatment movement analysis
• Fig. 19 U.S. androgenetic alopecia market: Treatment outlook and key takeaways
• Fig. 20 Pharmaceuticals market estimates and forecast, 2018 - 2030
• Fig. 21 Devices market estimates and forecast, 2018 - 2030
• Fig. 22 U.S. androgenetic alopecia market: End Use movement analysis
• Fig. 23 U.S. androgenetic alopecia market: End Use outlook and key takeaways
• Fig. 24 Homecare settings market estimates and forecasts, 2018 - 2030
• Fig. 25 Dermatology clinics market estimates and forecasts, 2018 - 2030
• Fig. 26 U.S. androgenetic alopecia market: Sales channel movement analysis
• Fig. 27 U.S. androgenetic alopecia market: Sales channel outlook and key takeaways
• Fig. 28 Prescriptions market estimates and forecasts, 2018 - 2030
• Fig. 29 OTC market estimates and forecasts, 2018 - 2030
• Fig. 30 U.S. androgenetic alopecia market: Gender movement analysis
• Fig. 31 U.S. androgenetic alopecia market: Gender outlook and key takeaways
• Fig. 32 Male market estimates and forecasts, 2018 - 2030
• Fig. 33 Female market estimates and forecasts, 2018 - 2030

U.S. Androgenetic Alopecia Market Trends:

The U.S. androgenetic alopecia market was valued at USD 979.1 million in 2024 and is expected to grow at a CAGR of 6.6% from 2025 to 2030. The increasing incidence of Androgenic Alopecia (AGA) is driving market growth. Androgenetic alopecia, the most common form of hair loss, affects a significant portion of the population, with aging and genetic factors playing a role. As awareness about hair loss solutions rises, more individuals seek treatments, expanding the market. According to data published by the National Library of Medicine in July 2023, approximately 50 million men and 30 million women in the U.S. were affected by androgenetic alopecia (AGA).

Another factor is the advancement in treatment options. The market has witnessed the introduction of innovative therapies, such as topical solutions, oral medications, and minimally invasive procedures such as platelet-rich plasma (PRP) therapy and hair transplant surgeries. Pharmaceutical companies also invest in research and development to create more effective and convenient treatments, attracting a broader consumer base.

The approval of new drugs and the expansion of over-the-counter products further propel market growth. In June 2025, Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405, a topical treatment targeting hair loss by reactivating dormant hair follicle stem cells. This advancement positions Pelage as a leader in regenerative medicine for androgenetic alopecia.

U.S. Androgenetic Alopecia Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. androgenetic alopecia market report based on treatment, end use, sales channel, and gender:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceuticals
• Devices
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Homecare Settings
• Dermatology Clinics
• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Prescriptions
• OTC
• Gender Outlook (Revenue, USD Million, 2018 - 2030)
• Male
• Female

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Sales Channel
  • 1.2.4. Gender
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Sales Channel Outlook
  • 2.2.4. Gender Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Androgenetic Alopecia Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Androgenetic Alopecia Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape
• 3.4. U.S. Androgenetic Alopecia Market: Pipeline Analysis

Chapter 4. U.S. Androgenetic Alopecia Market: Treatment Estimates & Trend Analysis

• 4.1. Treatment Segment Dashboard
• 4.2. U.S. Androgenetic Alopecia Market: Treatment Movement Analysis
• 4.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Pharmaceuticals
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Devices
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Androgenetic Alopecia Market: End Use Estimates & Trend Analysis

• 5.1. End Use Segment Dashboard
• 5.2. U.S. Androgenetic Alopecia Market: End Use Movement Analysis
• 5.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Homecare Settings
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Dermatology Clinics
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Androgenetic Alopecia Market: Sales Channel Estimates & Trend Analysis

• 6.1. Sales Channel Segment Dashboard
• 6.2. U.S. Androgenetic Alopecia Market: Sales Channel Movement Analysis
• 6.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 6.4. Prescriptions
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD million)
• 6.5. OTC
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis

• 7.1. Male
  • 7.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.2. Female
  • 7.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Johnson & Johnson Services, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Cipla
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Sun Pharmaceutical Industries Ltd.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Merck & Co., Inc
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Dr. Reddy's Laboratories Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Aurobindo Pharma Limited
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Hairmax International LLC
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Curallux, LLC
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Apira Science, Inc. (iGROW Laser)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Theradome Inc.
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives